Alzamend Neuro (NASDAQ:ALZN) Posts Earnings Results

Alzamend Neuro (NASDAQ:ALZN) issued its earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, Yahoo Finance reports.

Alzamend Neuro Trading Up 7.1 %

Shares of ALZN opened at $0.24 on Friday. The firm has a market capitalization of $23.14 million, a P/E ratio of -1.41 and a beta of 0.01. Alzamend Neuro has a 12-month low of $0.21 and a 12-month high of $1.50. The firm has a fifty day moving average price of $0.37 and a 200-day moving average price of $0.49.

Institutional Trading of Alzamend Neuro

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Alzamend Neuro by 6,642.3% in the third quarter. Vanguard Group Inc. now owns 4,095,775 shares of the company’s stock worth $4,874,000 after acquiring an additional 4,035,028 shares during the period. BlackRock Inc. purchased a new stake in Alzamend Neuro in the third quarter worth about $709,000. Renaissance Technologies LLC purchased a new stake in Alzamend Neuro in the second quarter worth about $56,000. Virtu Financial LLC purchased a new stake in Alzamend Neuro in the fourth quarter worth about $35,000. Finally, HRT Financial LP purchased a new stake in Alzamend Neuro in the fourth quarter worth about $32,000. 6.37% of the stock is owned by hedge funds and other institutional investors.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.